Literature DB >> 8420006

Blood-brain barrier penetration and in vivo activity of an NGF conjugate.

P M Friden1, L R Walus, P Watson, S R Doctrow, J W Kozarich, C Bäckman, H Bergman, B Hoffer, F Bloom, A C Granholm.   

Abstract

Nerve growth factor (NGF) is essential for the survival of both peripheral ganglion cells and central cholinergic neurons of the basal forebrain. The accelerated loss of central cholinergic neurons during Alzheimer's disease may be a determinant of dementia in these patients and may therefore suggest a therapeutic role for NGF. However, NGF does not significantly penetrate the blood-brain barrier, which makes its clinical utility dependent on invasive neurosurgical procedures. When conjugated to an antibody to the transferrin receptor, however, NGF crossed the blood-brain barrier after peripheral injection. This conjugated NGF increased the survival of both cholinergic and noncholinergic neurons of the medial septal nucleus that had been transplanted into the anterior chamber of the rat eye. This approach may prove useful for the treatment of Alzheimer's disease and other neurological disorders that are amenable to treatment by proteins that do not readily cross the blood-brain barrier.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8420006     DOI: 10.1126/science.8420006

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  47 in total

Review 1.  Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications.

Authors:  S I Rapoport
Journal:  Cell Mol Neurobiol       Date:  2000-04       Impact factor: 5.046

2.  Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination.

Authors:  J W Bulte; S Zhang; P van Gelderen; V Herynek; E K Jordan; I D Duncan; J A Frank
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

3.  Long-term functional recovery from age-induced spatial memory impairments by nerve growth factor gene transfer to the rat basal forebrain.

Authors:  A Martínez-Serrano; W Fischer; S Söderström; T Ebendal; A Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

Review 4.  Development of neuropeptide drugs that cross the blood-brain barrier.

Authors:  Richard D Egleton; Thomas P Davis
Journal:  NeuroRx       Date:  2005-01

5.  Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease.

Authors:  J Garcia de Yebenes; J Yebenes; M A Mena
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

6.  Targeted delivery of proteins across the blood-brain barrier.

Authors:  Brian J Spencer; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-26       Impact factor: 11.205

Review 7.  Mast cells in neuroimmune function: neurotoxicological and neuropharmacological perspectives.

Authors:  W M Purcell; C K Atterwill
Journal:  Neurochem Res       Date:  1995-05       Impact factor: 3.996

Review 8.  Developing therapeutic antibodies for neurodegenerative disease.

Authors:  Y Joy Yu; Ryan J Watts
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

9.  Transferrin-antibody fusion proteins are effective in brain targeting.

Authors:  S U Shin; P Friden; M Moran; T Olson; Y S Kang; W M Pardridge; S L Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

10.  Strategies for enhanced drug delivery to the central nervous system.

Authors:  V S N M Dwibhashyam; A N Nagappa
Journal:  Indian J Pharm Sci       Date:  2008 Mar-Apr       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.